Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Vertex Pharmaceuticals is a biotechnology business based in the US. Vertex Pharmaceuticals stocks (VRTX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $325.3 – a decrease of 2.72% over the previous week. Vertex Pharmaceuticals employs 4,800 staff and has a trailing 12-month revenue of around $9.2 billion.
Promoted
National Bank Direct Brokerage
Finder Award
Interactive Brokers
| Latest market close | $323.57 |
|---|---|
| 52-week range | $243.17 - $354.46 |
| 50-day moving average | $329.16 |
| 200-day moving average | $306.32 |
| Wall St. target price | $345.06 |
| PE ratio | 26.5907 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $12.41 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $323.57 from 2023-05-31
| 1 week (2023-05-25) | -2.72% |
|---|---|
| 1 month (2023-05-01) | -6.21% |
| 3 months (2023-03-01) | 11.10% |
| 6 months (2022-12-01) | 0.88% |
| 1 year (2022-05-28) | N/A |
|---|---|
| 2 years (2021-06-01) | 54.32% |
| 3 years (2020-06-01) | 12.88% |
| 5 years (2018-06-01) | 112.80% |
Valuing Vertex Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $9.2 billion |
|---|---|
| Operating margin TTM | 48.51% |
| Gross profit TTM | $5.3 billion |
| Return on assets TTM | 16.8% |
| Return on equity TTM | 25.73% |
| Profit margin | 35.4% |
| Book value | $56.05 |
| Market capitalisation | $85.7 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 30.84
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals's overall score of 30.84 (as at 01/01/2019) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 5.65/100
Vertex Pharmaceuticals's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.22/100
Vertex Pharmaceuticals's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.46/100
Vertex Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals has, for the most part, managed to keep its nose clean.
We're not expecting Vertex Pharmaceuticals to pay a dividend over the next 12 months.
Vertex Pharmaceuticals's shares were split on a 2:1 basis on 24 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals shares which in turn could have impacted Vertex Pharmaceuticals's share price.
Over the last 12 months, Vertex Pharmaceuticals's shares have ranged in value from as little as $243.17 up to $354.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals's is 0.4905. This would suggest that Vertex Pharmaceuticals's shares are less volatile than average (for this exchange).
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG. ; Moderna, Inc.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…Compare some of the best bad credit loans in PEI.
Your guide to the features, interest rates and fees to expect when you apply for a short-term loan with Credito.
Pay for unexpected bills and avoid overdrafts when you sign up for apps like Bree.
Take a closer look at the debt relief solutions, features and fees of Debt Relief Canada.
Learn more about Desjardins Online Brokerage (Disnat) to see if it’s the right broker for you.
We show you the best prepaid credit cards in Canada, whether you’re looking for a prepaid card with no fees, cash back rewards, or travel perks, or more.
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
Compare apps like Nyble in Canada to access emergency funding.
Your guide to buying and financing a car in Canada with RightRide.
Your guide to bad credit car loans in BC and how to find the right financing for your needs.
